On the contrary, glitazones (0.55; 0.35-0.86), DPP-4 inhibitors (0.57; 0.43-0.76) and GLP-1 analogues (0.48; 0.28-0.81) were associated with a reduced risk of hypoglycaemia. This evidence concerns the gene GCG and Hypoglycemia.